Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism
Metrics: PDF 1472 views | HTML 2327 views | ?
Baozhong Shen1,2, Tao Huang3,*, Yingying Sun1,2,*, Zhongnan Jin1,2 and Xiao-Feng Li1,2
1 PET/CT/MRI Center, The Fourth Hospital of Harbin Medical University, Harbin, China
2 Molecular Imaging Research Center, Harbin Medical University, Harbin, China
3 Department of Radiology, The Fourth Hospital of Harbin Medical University, Harbin, China
* These authors have contributed equally to this article
Baozhong Shen, email:
Xiao-Feng Li, email:
Keywords: 18F-FDG, positron emission tomography, cancer, hypoxia, glucose metabolism
Received: February 02, 2017 Accepted: March 11, 2017 Published: March 29, 2017
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography has become an important tool for detection, staging and management of many types of cancer. Oncology application of 18F-FDG bases on the knowledge that increase in glucose demand and utilization is a fundamental features of cancer. Pasteur effect, Warburg effect and reverse Warburg effect have been used to explain glucose metabolism in cancer. 18F-FDG accumulation in cancer is reportedly microenvironment-dependent, 18F-FDG avidly accumulates in poorly proliferating and hypoxic cancer cells, but low in well perfused (and proliferating) cancer cells. Cancer is a heterogeneous and complex “organ” containing multiple components, therefore, cancer needs to be investigated from systems biology point of view, we proposed the concept of “systems molecular imaging” for much better understanding systems biology of cancer.
This article revisits 18F-FDG uptake mechanisms, its oncology applications and the role of 18F-FDG PET for “systems molecular imaging”.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.